Molecular Diagnostics Point of Care Market Size, Share, Forecast Report 2026 to 2035
What is Molecular Diagnostics Point of Care Market Size?
Global Molecular Diagnostics Point of Care Market Size is valued at USD 3.63 Billion in 2025 and is predicted to reach USD 9.93 Billion by the year 2035 at a 11.1% CAGR during the forecast period for 2026 to 2035.
Molecular Diagnostics Point of Care Market Size, Share & Trends Analysis Reaport By Test Location (Over-the-Counter (OTC), PoC), By Technology (PCR-based, Genetic Sequencing-based, Hybridization-based, Microarray-based), By Application, By End-Use, By Region, And By Segment Forecasts, 2026 to 2035.
Molecular Diagnostics Point of Care Market Key Takeaways:
|
Key Industry Insights & Findings from the Report:
- The advent of the molecular diagnostic POC market represents a paradigm shift in healthcare accessibility, driving efficiency and quality of care improvements.
- The rising prevalence of infectious diseases like Cancer is expected to drive industry growth.
- North America dominated the market and accounted for a revenue share of global revenue in 2025.
- One of the significant concerns restraining industry growth is the limited reimbursement policies and infrastructural issues.
Medical professionals use tests known as molecular diagnostics point of care to identify and diagnose infectious disorders. Hematology, fertility, infectious diseases, pregnancy, urinalysis testing kits, and glucose and cardiometabolic monitoring equipment are all included. In addition to monitoring hemoglobin and fecal occult blood, molecular diagnostics point of care is frequently used to identify infectious agents, gastrointestinal diseases, and minimal residual disease and to assess a patient's capacity to metabolize a given medicine or class of drugs. These tests provide quicker answers, lessen difficulties brought on by improper care, and enhance infection prevention techniques.
The global spread of infectious diseases is expanding, which is good news for the market. Another element driving expansion is the increasing need for PCR test kits to properly manage and control the spread of COVID-19. Additionally, the development of user-friendly, low-cost, and highly sensitive molecular diagnostic tests using downsizing, nanotechnology, and microfluidics is accelerating the market's expansion.
Moreover, numerous government initiatives to enhance molecular diagnostic capabilities and healthcare infrastructure favourably affect market growth. In addition, the market is anticipated to grow due to recent breakthroughs in cloud-connected POC diagnostic technologies, rapid progress in deoxyribonucleic acid (DNA) sequencing, and growing public awareness of advanced therapeutic and diagnostic testing.
Competitive Landscape
Some major key players in the Molecular Diagnostics Point of Care Market:
- Abbott Laboratories,
- Bayer Healthcare,
- Roche Diagnostics,
- Bio-Rad Laboratories,
- Danaher Corporation,
- BioMerieux, Dako,
- Abaxis Inc.,
- OraSure Technologies Inc.
- Nipro Diagnostics.
Market Segmentation:
The molecular diagnostics point-of-care market is segmented on test location, technology, application and end-use. Based on test location, the market is segmented into over-the-counter (OTC) and PoC. Based on the technology, the market is categorized into PCR-based, genetic sequencing-based, hybridization-based and microarray-based. Based on the application, the market is segmented into infectious diseases, oncology, hematology, prenatal testing, endocrinology and others. Based on end-use, the market is categorized into decentralized labs, hospitals, homecare and assisted living healthcare facilities and others.
Based On Test Location, The Over The Counter (OTC) Category Is Accounted As A Major Contributor To The Molecular Diagnostics Point-Of-Care Market.
The over-the-counter (OTC) category dominated the market in 2021. Compared to POC testing, OTC tests are more adaptable and portable when used in homes and supportive living institutions. In most instances, patients and unqualified personnel make up the majority of OTC users. Additionally, a few of these test instruments are exempt from CLIA, allowing users to utilize them in settings other than laboratories. OTC tests are anticipated to generate more money during the forecasted period due to their simplicity, usefulness, and higher acceptance rate.
The PCR-Based Category Witnessed Growth At A Rapid Rate.
The PCR-based category dominated the market in 2021. The commercialization of PoC tests, which provide quick real-time PCR analysis with excellent precision for infectious illnesses like H1N1 and influenza, is driving the market. NGS-based molecular testing close to the patient is anticipated to increase significantly during the projected period due to numerous industry breakthroughs. This part is expected to be successful because of cutting-edge technological advancements that enable accurate genetic testing and quick diagnosis at the treatment site. Quick DNA analysis is anticipated to have significant expansion in the following years due to key industry competitors' ongoing development and R&D.
The North American Molecular Diagnostics Point-Of-Care Market Holds A Significant Revenue Share In The Region.
The North American molecular diagnostics point-of-care market is expected to register the highest market share in revenue in the near future. The rising incidence of infectious diseases, increasing CLIA product approvals, and expanding legislative measures are driving this market's expansion in North America. The ongoing efforts of major market players to strengthen their position are a crucial contributing factor.
Several clinical trials will contribute to market growth throughout the projection period due to the diversity and precision of contemporary molecular tests. In addition, Asia Pacific is projected to grow rapidly in the global molecular diagnostics point-of-care market. The Asia Pacific molecular diagnostics point-of-care market is driven by factors including the aging population's increased prevalence of chronic diseases, a lack of highly developed central laboratory testing services, the growth of major market players in this region, and the potential cost-effectiveness of molecular diagnostics point-of-care.
Recent Developments:
- In February 2022, Sense Biodetection entered into a strategic agreement with Una Health (Una) for the United Kingdom distribution of the Veros Covid-19 test.
- In December 2021, FIND invested USD 21 million in Biomeme, Bioneer, Qlife, and SD Biosensor to accelerate the development, manufacturing, and launch of affordable point-of-care molecular diagnostic platforms that can detect multiple pathogens that cause diseases including COVID-19.
Molecular Diagnostics Point of Care Market Report Scope :
| Report Attribute | Specifications |
| Market Size Value In 2025 | USD 3.63 Billion |
| Revenue Forecast In 2035 | USD 9.93 Billion |
| Growth Rate CAGR | CAGR of 11.1% from 2026 to 2035 |
| Quantitative Units | Representation of revenue in US$ Billion and CAGR from 2026 to 2035 |
| Historic Year | 2022 to 2025 |
| Forecast Year | 2026-2035 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | Test Location, Technology, Application, End-Use |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
| Competitive Landscape | Abbott Laboratories, Bayer Healthcare, Roche Diagnostics, Bio-Rad Laboratories, Danaher Corporation, BioMerieux, Dako, Abaxis Inc., OraSure Technologies Inc. and Nipro Diagnostics. |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Segmentation of Molecular Diagnostics Point of Care Market :
Molecular Diagnostics Point of Care Market, By Test Location-
- Over-the-Counter (OTC)
- PoC
Molecular Diagnostics Point of Care Market, By Technology-
- PCR-based
- Genetic Sequencing-based
- Hybridization-based
- Microarray-based
Molecular Diagnostics Point of Care Market, By Application-
- Infectious Diseases
- Oncology
- Hematology
- Prenatal Testing
- Endocrinology
- Others
Molecular Diagnostics Point of Care Market, By End-Use-
- Decentralized Labs
- Hospitals
- Homecare
- Assisted Living Healthcare Facilities
- Others
Molecular Diagnostics Point of Care Market, By Region-
- North America-
- The US
- Canada
- Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
- Latin America-
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Molecular Diagnostics Point of Care Market Size is valued at USD 3.63 Billion in 2025 and is predicted to reach USD 9.93 Billion by the year 2035
Molecular Diagnostics Point of Care Market is expected to grow at a 11.1% CAGR during the forecast period for 2026 to 2035.
Abbott Laboratories, Bayer Healthcare, Roche Diagnostics, Bio-Rad Laboratories, Danaher Corporation, BioMerieux, Dako, Abaxis Inc., OraSure Technologies Inc., Nipro Diagnostics and Other.
Molecular Diagnostics Point of Care Market is segmented into Test Location (Over-the-Counter (OTC), PoC), By Technology (PCR-based, Genetic Sequencing-based, Hybridization-based, Microarray-based), By Application, By End-Use and Other.
North America region is leading the Molecular Diagnostics Point of Care Market.